237 related articles for article (PubMed ID: 22998153)
21. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.
Roth DA; Kessler CM; Pasi KJ; Rup B; Courter SG; Tubridy KL;
Blood; 2001 Dec; 98(13):3600-6. PubMed ID: 11739163
[TBL] [Abstract][Full Text] [Related]
22. Characterisation of recombinant factor IX before and after GlycoPEGylation.
Nielsen FS; Schmidt AS; Kristensen AK; Nielsen AD; Kristensen BK; Palm L
Int J Pharm; 2020 Oct; 588():119654. PubMed ID: 32693290
[TBL] [Abstract][Full Text] [Related]
23. In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients.
Preijers T; Hazendonk HCAM; Fijnvandraat K; Leebeek FWG; Cnossen MH; Mathôt RAA
J Thromb Haemost; 2017 Sep; 15(9):1737-1746. PubMed ID: 28688133
[TBL] [Abstract][Full Text] [Related]
24. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.
Brinkhous KM; Sigman JL; Read MS; Stewart PF; McCarthy KP; Timony GA; Leppanen SD; Rup BJ; Keith JC; Garzone PD; Schaub RG
Blood; 1996 Oct; 88(7):2603-10. PubMed ID: 8839853
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of rFIXFc versus N9-GP Prophylaxis in Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PARADIGM 2 Trials.
Mancuso ME; Eriksson D; Falk A; Hakimi Z; Wojciechowski P; Wdowiak M; Klamroth R
J Blood Med; 2023; 14():427-434. PubMed ID: 37534261
[TBL] [Abstract][Full Text] [Related]
26. Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real-world, multicenter, retrospective study.
Matino D; Iorio A; Keepanasseril A; Germini F; Caillaud A; Carcao M; Hews-Girard J; Iserman E; James P; Lee A; Phua CW; Sun HL; Teitel J; Poon MC
Res Pract Thromb Haemost; 2022 Mar; 6(3):e12661. PubMed ID: 35386274
[TBL] [Abstract][Full Text] [Related]
27. Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients.
Chan AK; Alamelu J; Barnes C; Chuansumrit A; Garly ML; Meldgaard RM; Young G
Res Pract Thromb Haemost; 2020 Oct; 4(7):1101-1113. PubMed ID: 33134776
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis.
Björkman S; Shapiro AD; Berntorp E
Haemophilia; 2001 Mar; 7(2):133-9. PubMed ID: 11260271
[TBL] [Abstract][Full Text] [Related]
29. Steady-State Plasma Concentrations of Polyethylene Glycol (PEG) are Reached in Children and Adults During Once-Weekly Prophylactic Treatment with Nonacog Beta Pegol (N9-GP).
Sternebring O; Gabel-Jensen C; Jacobsen H; Benie AJ; Bjørnsdottir I
BioDrugs; 2019 Dec; 33(6):673-681. PubMed ID: 31549312
[TBL] [Abstract][Full Text] [Related]
30. Normal Neurodevelopment and Fertility in Juvenile Male Rats Exposed to Polyethylene Glycol Following Dosing With PEGylated rFIX (Nonacog Beta Pegol, N9-GP): Evidence from a 10-Week Repeat-Dose Toxicity Study.
Jensen VFH; Schefe LH; Jacobsen H; Mølck AM; Almholt K; Sjögren I; Dalsgaard CM; Kirk RK; Benie AJ; Petersen BO; Kyhn MS; Overgaard AJ; Bjørnsdottir I; Stannard DR; Offenberg HK; Egecioglu E
Int J Toxicol; 2022 Dec; 41(6):455-475. PubMed ID: 36036386
[TBL] [Abstract][Full Text] [Related]
31. Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX-Fc fusion protein: A randomized trial.
Escuriola Ettingshausen C; Hegemann I; Simpson ML; Cuker A; Kulkarni R; Pruthi RK; Garly ML; Meldgaard RM; Persson P; Klamroth R
Res Pract Thromb Haemost; 2019 Apr; 3(2):268-276. PubMed ID: 31011711
[TBL] [Abstract][Full Text] [Related]
32. Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomes.
Iorio A; MacDonald V; Caillaud A; Luckevich MD; Christoffersen P; Matino D; Keepanasseril A; Iserman E; Germini F; Bentley A; Poon MC
Res Pract Thromb Haemost; 2023 Mar; 7(3):100106. PubMed ID: 37065846
[TBL] [Abstract][Full Text] [Related]
33. Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product.
Chowdary P; Kearney S; Regnault A; Hoxer CS; Yee DL
Haemophilia; 2016 Jul; 22(4):e267-74. PubMed ID: 27352908
[TBL] [Abstract][Full Text] [Related]
34. High variability in Factor IX one-stage assay in samples spiked with nonacog beta pegol among different pairs of reagent/detection system.
Duboscq C; Sueldo E; Rosa C; Zirpoli M; Ceresetto J; Baques A; Arias M
Int J Lab Hematol; 2024 Feb; 46(1):128-134. PubMed ID: 37704365
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of plasma-derived and recombinant factor IX - implications for prophylaxis and on-demand therapy.
Björkman S
Haemophilia; 2013 Nov; 19(6):808-13. PubMed ID: 23786333
[TBL] [Abstract][Full Text] [Related]
36. Nonacog Beta Pegol: A Review in Haemophilia B.
Syed YY
Drugs; 2017 Dec; 77(18):2003-2012. PubMed ID: 29124682
[TBL] [Abstract][Full Text] [Related]
37. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial.
Collins PW; Young G; Knobe K; Karim FA; Angchaisuksiri P; Banner C; Gürsel T; Mahlangu J; Matsushita T; Mauser-Bunschoten EP; Oldenburg J; Walsh CE; Negrier C;
Blood; 2014 Dec; 124(26):3880-6. PubMed ID: 25261199
[TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery.
Preijers T; Hazendonk HCAM; Liesner R; Chowdary P; Driessens MHE; Hart D; Keeling D; Laros-van Gorkom BAP; van der Meer FJM; Meijer K; Fijnvandraat K; Leebeek FWG; Collins PW; Cnossen MH; Mathôt RAA;
J Thromb Haemost; 2018 Nov; 16(11):2196-2207. PubMed ID: 30394056
[TBL] [Abstract][Full Text] [Related]
39. Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B.
Zhang Y; Roberts J; Bensen-Kennedy D; Jacobs I; Santagostino E; Voigt C; Feussner A; Morfini M; Sidhu J
J Thromb Haemost; 2016 Nov; 14(11):2132-2140. PubMed ID: 27513989
[TBL] [Abstract][Full Text] [Related]
40. Performance of factor IX extended half-life product measurements in external quality control assessment programs.
Nederlof A; Kitchen S; Meijer P; Cnossen M; Ali Pour N; Kershaw G; Jennings I; Walker I; de Maat MPM
J Thromb Haemost; 2020 Aug; 18(8):1874-1883. PubMed ID: 32311825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
